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ABSTRACT 
 
 
Background: Arterial Hypertension (AHT) and its development are associated with structural, 
functional and genomic expression alterations in several organs, which all contribute to 
cardiovascular risk. In conditions when AHT is uncontrolled genomic expression can change, 
accelerate organ damage and ultimately results in organ failure. In previous studies, we have 
shown that chronic overexpression of an inwardly rectifying potassium channel (hKir2.1) in the 
paraventricular nucleus of the hypothalamus (PVN) and in the rostral ventrolateral medulla 
(RVLM), to suppress neuronal excitability, resulted in a long term decrease of blood pressure 
and sympathetic output in spontaneously hypertensive rats (SHR) but it remains unclear 
whether the pathological changes in gene expression relating to end organ structure are 
normalised. 
 
 
Objective: To evaluate gene expression changes in tissues controlling blood pressure (the heart, 
kidney and common carotid artery) induced by chronic overexpression of hKir2.1 channels in 
either the PVN or RVLM. 
 
 
Methods: We recently demonstrated in radio-telemetered spontaneously hypertensive rats 
(SHR) that overexpression of hKir2.1 in the PVN or RVLM decreased blood pressure and 
sympathetic output (−22±6 mmHg and -0.37±0.11 mmHg2ms-2 in PVN and -40±10 mmHg and -
0.27±0.11 mmHg2ms-2 in RVLM). The mRNA levels of 13 pre-selected genes known to be 
involved with blood pressure regulation were evaluated using real-time polymerase chain 
reaction (RT-PCR) in tissue from the kidney, heart and common carotid artery of hKir2.1 SHR, 
sham SHR and normotensive rats. 
 
 
Results: In hearts from SHR in which either the PVN or RVLM were injected with LVhKir2.1, there 
was a downregulation of angiotensin II receptor, type 1a (AT1), ATPase, Ca2+ transporter type 
2C1 (ATP2C1) and troponin T type 2 (Tnnt2) relative to the sham group. Also, tropomyosin 2, 
beta (Tpm2) was down-regulated in hearts from SHR injected in RVLM. In the kidney of SHR with 
LVhKir2.1 injections in PVN and RVLM, angiotensinogen, angiotensin II receptor type 2 (AT2) and 
endothelin 1 (ET-1) were all upregulated compared to sham. In the carotid artery, endothelin 2 
(ET-2) was up-regulated following LVhKir2.1 in to either the PVN or RVLM relative to sham. 
 
Conclusion: Central modulation of PVN or RVLM neuronal excitability that promotes a decrease 
in blood pressure and sympathetic activity affected gene expression in three end-organs, mainly 
through the up-regulation of angiotensinogen and AT-2 genes in the kidney and down-
regulation of AT-1 in the heart. These results provide new insights into the molecular 
mechanisms underlying the potential efficacy of chronic overexpression of hKir2.1 channels in 
central sympathoexcitatory areas in protecting against end-organ damage in essential 
hypertension and thus reveal peripheral targets for therapeutic manipulation in hypertension. 
1. INTRODUCTION 
 
Arterial Hypertension (AHT) and its development are associated with chronic activation of the 
sympathetic nervous system along with alterations in structural, functional and genomic 
expression in several organs, in particular in target organs such as the brain, heart, kidney and 
vasculature, all of which contribute to cardiovascular risk. 
 
In conditions when AHT is uncontrolled, genomic expression and transcriptomic alterations can 
evoke changes in different signal-transducing cascades, thus, accelerating end-organ damage which 
ultimately results in organ failure and secondary disease such as stroke, cardiac ischemia and 
nephropathy (REFRENCES). An elevated blood pressure can also cause left ventricular hypertrophy, 
aortic stiffness, atherosclerotic plaques and microvascular disease that may render AHT more 
difficult to control (Muiesan ML, 2013; Cecelja M, 2012; Ausiello D, 2003). 
 
In previous studies, we have shown that chronic overexpression of an inwardly rectifying 
potassium channel (hKir2.1) in the paraventricular nucleus of the hypothalamus (PVN) and in the 
rostral ventrolateral medulla (RVLM), to suppress neuronal excitability, resulted in a long term 
(8 weeks) decrease of blood pressure and sympathetic output to cardiovascular system in 
spontaneously hypertensive rats (SHR) but not in normotensive Wistar Kyoto (WKY) rats. 
However, it remains unclear whether the pathological changes in gene expression relating to 
end organ structure in the SHR can be normalised when arterial pressure and sympathetic tone 
are reduced by hKir2.1 overexpression in the PVN and RVLM. Thus, the present study has used 
quantitative real-time pcr analysis to assess whether genes expected to be altered in 
cardiovascular pathologies (e.g., renin-angiotensin system, nitric oxide metabolism and 
signalling, vasoconstrictiors and dilators) can be rescued following a chronic lowering of blood 
pressure and sympathetic activity centrally in the heart, kidney and common carotid artery) of 
the SHR. 
 
 
 
2. MATERIALS AND METHODS 
 
All the experimental procedures were in accordance with the European and Portuguese Law on 
animal welfare and had the approval of the ethic committee of the Faculty of Medicine, 
University of Lisbon, Portugal. WKY rats (n=7) and SHRs (n=18), males, aged 12 weeks and 
weighing 363±8g, were used. SHR rats were bilaterally microinjected with LV-hKir2.1 (LV-
TREtight-Kir-cIRES-GFP 5.4x10E9 and LV-Syn-Eff-G4BS-Syn-Tetoff 6.2x10E9 in a ratio 1:4) into 
the PVN or RVLM. SHAM rats were bilaterally microinjected in the same regions with LV-eGFP 
 
(LV-TREtight-GFP 5.7x10E9 and LV-Syn-Eff-G4BS-Syn-Tetoff 6.2x10E9 in a ratio 1:4) as shown in 
previous studies (Geraldes et al., 2014a; Geraldes et al, 2014b). 
 
 
 
2.1. Organ tissue processing, RNA isolation and cDNA Synthesis 
 
Animals were killed with an overdose of anesthesia (pentobarbital, 50 mg/kg, i.v.) and the target 
organs (whole heart, common carotid artery and whole kidney) were excised, immediately 
frozen separately in liquid nitrogen and stored at −80 ◦C for subsequent RNA isolation. 
 
The heart, common carotid artery and kidney of individual LVhKir2.1 injected SHR, Sham SHR 
and WKY rats were grinded with a mortar and pestle in liquid nitrogen and approximately 50mg 
of powdered tissue was homogenized in Tri Reagent® Solution (Ambion) for total RNA isolation 
according to the manufacturer’s instructions. RNA concentration was estimated by measuring 
the absorbance at 260nm and its purity assessed by determining the 260/280nm absorbance 
ratio using NanoDrop 1000A (Thermo Scientific). First strand cDNA was synthesized from 1µg of 
total RNA using High Capacity cDNA Reverse Transcription Kit (Applied 
 
Biosystems), according to the manufacturer’s instructions. 
 
 
 
2.2. Quantitative real-time PCR analysis 
 
Oligonucleotide primers were designed with Primer Express ® Software Version 3.0 (Applied 
Biosystems) according to the recommended parameters for quantitative assays, based on the 
mRNA sequences obtained from the Rat Genome Database. Gene ID and oligonucleotide 
sequences are listed in Table 1. The chosen genes are known to be involved in various processes 
including blood pressure regulation, renin-angiotensin system, nitric oxide metabolism and 
signalling, vasoconstriction/vasodilatation, osmotic shock, ion transport, nitric oxide 
metabolism, hypoxia response and vasotone. 
 
RNA concentration was determined by measuring its absorbance in the NanoDrop 1000A 
(Thermo Scientific). The A260/A280 ratio of RNA 260/A280 ratios exceeded 1.9 showing minimal 
protein contamination. 
 
Real-time PCR reactions were performed on a 7500 Fast Real-Time PCR System (Applied 
 
Biosystems) using Fast SYBR® Green Master Mix reagents, following the manufacturer’s 
protocol. Immediately after amplification, melt curve analysis was performed in order to check 
 
PCR reactions for primer-dimer artifacts and to ensure specificity. To confirm accuracy and 
reproducibility of real-time PCR the intra-assay precision was determined in three repeats. 
 
Table 1 - Primers and respective sequences designed for Real Time PCR 
 
Gene name (Symbol) Primer sequence 
Accession number Forward/Reverse 
  
Angiotensinogen (Agt) CCCTGAGCAGTCCGTTCCT 
NM_134432 AAAGTGCAGCGCACCTGAGT 
  
Angiotensin II receptor, type 1a (AT1a) GCCAGGGCAGCCTCTGA 
NM_030985 TCCTGAGGCAGGGTGAATG 
  
Angiotensin II receptor, type 1b (AT1b) CCTCCGCCGCACGAT 
NM_ 112271 CCATTAGCCAGATGATGATGCA 
  
Angiotensin II receptor, type 2 (AT2) TGCTGTTGTGTTGGCATTCA 
NM_012494 ATCCAAGAAGGTCAGAACATGGA 
  
ATPase, Ca++ transporting, type 2C, member 1 (Atp2c1) TGGAACCCTGACGAAGAATGA 
NM_131907 GCATGCAGGCCGTCTGA 
  
Endothelin 1 (ET-1) TGGAGGCCATCAGCAACAG 
NM_012548 AGTTCCGCTTTCAACTTTGCA 
  
Nitric  oxide  synthase  3,  endothelial  cell  (Nos3) TCTTTCGGAAGGCGTTTGAC 
NM_021838 CTCTAGGGATACCACATCGTATTCATC 
  
Renin (Ren) CTGCTCAGGCTGTTGATGGA 
NM_012642 CACCCTCTGGGAGAGAATGTG 
  
Troponin T type 2 (cardiac) (Tnnt2) CAGGAAGCGCATGGAGAAG 
NM_012676 TCGAAGTGAGCCTCGATCAGA 
  
Tropomyosin 1, alpha (Tpm1) GGCCAAGCACATTGCTGAA 
NM_019131 GCTTACGGGCCACCTCTTC 
  
Tropomyosin 2, beta (Tpm2) TAACCTGTCCCGGGTGCAT 
NM_001024345 GCGAGCGGTGAAGAGTAGGTA 
  
myosin, heavy chain 6, cardiac muscle, alpha (Myh6) ACAGAGTGCTTCGTGCCTGAT 
NM_017239 CAGTCACCGTCTTGCCGTTT 
  
myosin, heavy chain 7, cardiac muscle, beta (Myh7) CAGCCTACCTCATGGGACTGA 
NM_017240 TGACATACTCGTTGCCCACTTT 
  
Actin, beta ACCAGTTCGCCATGGATGAC 
ActB/ NM_031144 TGCCGGAGCCGTTGTC 
 
 
The relative quantification of gene expression in LVhKir2.1 injected SHR, sham SHR and WKY samples was 
determined by comparative C(t) method, using the normotensive WKY group as a calibrator to estimate 
the relative amount of mRNA in both SHR groups. The mRNA level of all samples was normalized against 
an endogenous control (β-actin). The fold-change for the SHR samples relative to WKY was calculated by 
2− ( ), where ( ) = ( ) − 
( )    ,and   ( ) ( ) −  ( ) . 
2.3. Ventricular wall measurements 
 
Thicknesses of the left and right ventricular wall were evaluated in WKY, sham SHR and LVhKir2.1 
injected SHR rats. Thicknesses were determined with a microscope (Olympus CX41) set at a total 
magnification of ×5. 
 
 
 
2.4. Statistical analysis 
 
Comparisons between groups for the same period and also comparisons within the same group, 
before and after the microinjections were performed. For the statistical analysis, 
 
Student’s t test for paired data and ANOVA for comparisons between inter-groups were used. All 
data were expressed as mean±SEM and passed the normality test. Significance was taken as 
 
P < 0.05. 
 
 
 
 
3. RESULTS 
 
3.1. Lentiviral effect on blood pressure and sympathetic output 
 
We recently demonstrated in radio-telemetered spontaneously hypertensive rats (SHR) that the 
overexpression of hKir2.1 in the PVN or RVLM of conscious unrestrained SHR, caused a marked 
and sustained decrease in blood pressure and sympathetic output as revealed indirectly by a 
decrease in the power density of the Low frequency (LF) band of systolic blood pressure (−22±6 
mmHg and -0.37±0.11 mmHg2ms-2 in PVN and -40±10 mmHg and -0.27±0.11 mmHg2ms-2 in 
RVLM) (Geraldes et al., 2014a; Geraldes et al, 2014b). At the same time, SHR SHAM group were 
showing increased values of blood pressure, consistent with their developmental trend. 
 
 
 
3.2. Changes in gene expression in the heart, common carotid artery and kidney induced by 
 
LV-hKir2.1 treatment 
 
The present study was designed to identify which genes known to be involved in end-organ 
damage. In hypertension are changed in expression by LV-hKir2.1 injection in either the PVN or 
RVLM in individual end-organs. 
 
Using RT-PCR, the expression profile of 16 genes was analyzed in the heart, common carotid 
artery and kidneys in LVhKir2.1 injected SHR, Sham SHR and sham WKY rats. The genes 
quantified for each target organ are shown in Table 2. The results are shown as below separately 
for each gene, tissue and microinjected area (Figure 1 to 3; Table 3, 4 and 5). A summary of 
mRNA expression changes in the 3 end-organs of LVhKir2.1 injected PVN and RVLM is presented 
in figure 4. 
 
Table 2 - Selected genes and samples analyzed 
 
Gene Target Organ Sample 
 
  
 
angiotensinogen (Agt) Kidney 
 
  
 
angiotensin II receptor, type 1a (AT1a) Kidney 
 
  
 
angiotensin II receptor, type 1b (AT1b) Kidney, Heart 
 
  
 
angiotensin II receptor, type 2 (AT2) Kidney 
 
  
 
ATPase, Ca++ transporting, type 2C, 
Kidney, Heart  
member 1 (Atp2c1)   
 
   
endothelin 1 (ET-1) Kidney, Heart, Carotid 
 
  
 
endothelin 2 (ET-2) Carotid 
 
  
 
endothelin receptor type A (Ednra) Carotid 
 
  
 
endothelin receptor type B (Ednrb) Carotid 
 
  
 
nitric oxide synthase 3, endothelial cell 
Kidney, Heart  
(Nos3)   
 
   
renin (Ren) Kidney 
 
  
 
troponin T type 2 (cardiac) (Tnnt2) Heart 
 
  
 
tropomyosin 1, alpha (Tpm1) Heart 
 
  
 
tropomyosin 2, beta (Tpm2) Heart 
 
  
 
myosin, heavy chain 6, cardiac muscle, 
Heart  
alpha (Myh6)   
 
   
myosin, heavy chain 7, cardiac muscle, 
Heart  
beta (Myh7)   
 
   
actin, beta (Actb) Kidney, Heart, Carotid 
  
 
 
3.2.1. Changes in mRNA expression in the heart 
 
mRNA expression in PVN LVhKir2.1 injected SHR was similar to WKY rats. In the RVLM LVhKir2.1 
injected SHR among the 9 genes studied only 1 was down-regulated – myosin 7 - compared with 
WKY group (Figure 1, table 3). 
 
Comparing the mRNA expression in LVhKir2.1 injected SHR with the SHR sham: AT1, ATP2C1 and 
Tnnt2 were down-regulated in LVhKir2.1 injected PVN SHR and in LVhKir2.1 injected RVLM SHR. 
Also, Tpm2 was down-regulated in LVhKir2.1 injected RVLM SHRs (table 3). 
 
 
 
 
Table 3 - mRNAs Expression in the heart of SHR after the treatment with LV-hKir2.1 in the PVN and in 
 
the RVLM relative to WKY group or to SHR SHAM group. *p<0.05; **p<0.01. 
 
PVN SHR Fold change Fold change RVLM SHR Fold change Fold change 
Genes relative to WKY relative to SHAM Genes relative to WKY relative to SHAM 
      
AT1 1,36 0,26* AT1 1,38 0,26* 
      
Atp2C1 0,74 0,38** Atp2C1 0,78 0,40** 
      
ET-1 1,25 2,05 ET-1 1,65 2,35 
      
Myh6 0,62 0,85 Myh6 0,49 0,68 
      
Myh7 0,43 0,76 Myh7 0,28* 0,72 
      
NOS3 0,57 1,19 NOS3 0,98 2,05 
      
Tnnt2 0,70 0,36
* Tnnt2 0,76 0,50
* 
      
Tpm1 0,78 0,43 Tpm1 0,77 0,42 
      
Tpm2 1,34 0,99 Tpm2 1,08 0,34* 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – mRNA expression in the heart of LVhKir2.1 injected PVN and RVLM SHR and SHR SHAM 
 
relative to WKY rats. AT1, angiotensin II receptor type 1; Atp2C1, ATPase, Ca++ transporting, type 2C, 
member 1; ET-1, endothelin 1; Myh6, Myosin 6; Myh7, Myosin 7; Nos3, Nitric oxide synthase 3, 
endothelial cell; Tnnt2, Troponin T type 2; Tpm1, Tropomyosin 1, alpha; Tpm2, Tropomyosin 2, beta. 
*p<0.05 compared to WKY rats and #p<0.05; ##p<0.01 compared to SHAM rats. 
 
 
 
3.2.2. Expression changes in the kidney 
 
Comparing the mRNA expression in LVhKir2.1 injected SHR (PVN and RVLM) with WKY rats 2 of 
8 genes were up-regulated – endothelin 1 and AT2, respectively (Figure 2, table 4). 
 
Comparing the mRNA expression in LVhKir2.1 injected SHR with sham SHR rats: 3 genes were 
up-regulated – Angiotensinogen, AT2 and ET-1 in LVhKir2.1 injected PVN SHR and in LVhKir2.1 
injected RVLM SHR, respectively (table 4). 
 
 
Table 4 - mRNAs Expression in the kidney of SHR after the treatment with LV-hKir2.1 in the PVN and in 
 
the RVLM, relative to WKY group or to SHR SHAM group. *p<0.05; **p<0.01; ***p<0.001 
 
PVN SHR Fold change Fold change RVLM SHR Fold change Fold change 
Genes relative to WKY relative to SHAM Genes relative to WKY relative to SHAM 
      
Agt 1,09 1,91** Agt 1,51 2,67** 
      
AT1a 1,10 0,80 AT1a 1,16 0,85 
      
AT1b 0,85 0,59 AT1b 1,60 1,10 
      
AT2 2,20
* 11,10* AT2 8,34
* 42,10*** 
      
Atp2C1 1,20 1,55 Atp2C1 1,01 1,31 
      
ET-1 3,06
*** 8,47*** ET-1 5,30
*** 14,69*** 
      
NOS3 0,62 0,50 NOS3 0,83 0,66 
      
Ren 1,21 0,71 Ren 1,52 0,89 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – mRNA expression in the kidney of LVhKir2.1 injected PVN and RVLM SHR and SHR SHAM 
 
relative to WKY rats. Agt, Angiotensinogen; AT1a, angiotensin II receptor type 1a; AT1b, angiotensin II receptor 
type 1b; AT2, angiotensin II receptor type 2; Atp2C1, ATPase, Ca++ transporting, type 2C, member 1; ET-1, 
endothelin 1; Nos3, Nitric oxide synthase 3, endothelial cell; Ren, Renin. *p<0.05; **p<0.01; ***p<0.001 
compared to WKY rats and #p<0.05; ##p<0.01; ###p<0.001 compared to SHAM rats. 
 
 
3.2.3. Expression changes in the common carotid artery 
 
In LVhKir2.1 injected PVN SHR, among the 4 genes studied one was up-regulated - endothelin 
receptor type A (Ednra) – compared with WKY rats (Figure 3, Table 5). Comparing the mRNA 
expression in LVhKir2.1 injected PVN SHR with sham SHR rats, 1 gene was up-regulated - 
endothelin-2 (ET-2) (Figure 3, table 5). 
 
In LVhKir2.1 injected RVLM SHR, 1 gene was up-regulated – endothelin receptor type A (Ednra) 
- compared with WKY rats (table 5). Compared to the sham SHR group there was an up-
regulation of ET-2 in RVLM LVhKir2.1 injected SHR (table 5). 
 
 
 
Table 5 - mRNAs Expression in the common carotid artery of SHR after the treatment with LV-hKir2.1 in 
the PVN and in the RVLM relative to the WKY group or to SHR SHAM group. *p<0.05 
 
PVN SHR Fold change Fold change RVLM SHR Fold change Fold change 
Genes relative to WKY relative to SHAM Genes relative to WKY relative to SHAM 
      
ET-1 1,54 1,09 ET-1 1,38 0,97 
      
ET-2 3,29 4,76
* ET-2 2,06 2,99
* 
      
Ednra 1,70* 2,55 Ednra 1,49* 1,75 
      
Ednrb 2,26 2,94 Ednrb 1,75 2,27 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – mRNA expression in the common carotid artery of LVhKir2.1 injected PVN and RVLM SHR 
 
and SHR SHAM relative to WKY rats. ET-1, endothelin 1; ET-2, endothelin 2; Ednra, endothelin receptor 
 
type A; Ednrb, endothelin receptor type B. *p<0.05;***p<0.001. 
 
 
 
3.3 Effects of the LV-hkir2.1 microinjection on ventricular (LV) wall thickness in SHR 
 
Sham SHR animals had significantly elevated heart weight compared to WKY rats, with an 
increase of 11±3%. Also, the left ventricle thickness/right ventricle thickness ratio was increased 
significantly by 181±8% in sham SHRs compared with WKY rats (p<0.05). These data indicate, as 
expected, hypertrophy in SHRs. 
 
The LVhKir2.1 injected SHR showed a reduction of heart weight (12±3%) compared with sham 
SHR rats. The left ventricle thickness/right ventricle thickness ratio was also decreased by 51±6% 
in LVhKir2.1 injected SHRs compared with sham SHR rats (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Summary of mRNA expression changes in the common carotid artery, heart and kidney of 
LVhKir2.1 injected PVN and LVhKir2.1 injected RVLM compared to SHR SHAM. 
 
4. DISCUSSION 
 
We previously showed that a decrease in neuronal excitability within PVN and RVLM of SHR 
caused a chronically sustained decrease in blood pressure and sympathetic output (Duale et al., 
2005a, Duale et al., 2005b, Geraldes et al., 2013). In order to determine if the decrease in central 
neuronal excitability induced by the chronic overexpression of hKir2.1 channels in the PVN and 
RVLM reversed pathological remodeling in target organs, we evaluated gene 
 
expression changes in the heart, common carotid artery and kidneys, some of the major end-
organs associated with arterial hypertension (HTA). 
 
Our main finding of the present study was that treatment of LV-hKir2.1 in the PVN and RVLM of 
SHR can promote a remodeling process in target organs, as shown by the different regulation of 
gene expression in cardiac, common carotid artery and renal tissues. 
 
a) Heart and common carotid artery 
 
Cardiac hypertrophy is one of the major hypertension-induced pathological consequences. 
Taking in to account the 9 genes evaluated in the present study, only 1 was different from WKY 
rats, namely the myosin heavy chain β (β-MHC or Myh7) was downregulated in LVhKir2.1 
injected RVLM SHR. β-MHC 7 is involved in the regulation of contractility or hypertrophy. In 
normal cardiac tissue the myosin heavy chain α (α-MHC; v1 cardiac myosin) is expressed 
predominantly, but in models of cardiac hypertrophy, the β-MHC has a higher expression than 
the α-MHC (Mercadier et al., 1981). 
 
Compagno showed that the β-MHC was markedly expressed in the ventricle of 15-week old SHR 
vs WKY (Compagno et al., 2001). Another study showed that after angiotensin II type 1 (AT1) 
receptor antagonist treatment, SHR showed BP decrease and downregulation of myosin heavy 
chain isoforms in smooth muscle cells of the aortic tunica media, that is similar to what 
happened to the Myh7 gene in the heart of LVhKir2.1 rats in the present study (Fujii et al., 1999). 
 
There was no significant difference in the expression of AT1 receptor, ATPase Ca2+( ATP2C1), 
Endothelin-1, Myosin 6, Nitric oxide synthase 3, Troponin T2 (Tpm2), Tropomyosin 1 (α) and 
Tropomyosin 2 (β) in the heart following LVhKir2.1 injections in PVN and RVLM between SHR 
and WKY rats. Previous studies showed differences in the expression of these genes in SHR vs 
WKY rats indicating remodeling processes in the heart of LVhKir2.1 injected SHR. In fact, the AT1 
receptor is up-regulated and there is evidence indicating a decrease in ATPase Ca2+ expression 
is prominent in hypertrophy and in heart failure, however it was shown that the expression of 
SR ATPase Ca2+ was not down-regulated in the heart of 11 week old SHR (Ohta et al., 1995). In 
addition, consistent with our findings in SHAM animals, other studies showed that troponin is 
up-regulated and NO synthase is downregulated in the heart of SHR in comparison with the WKY 
rats (Bauersachs et al., 1998; Piech et al., 2003). LVhKir2.1 microinjection in PVN or RVLM 
promoted a significant troponin down-regulation when compared to SHAM SHR. 
 
In the heart of LVhKir2.1 injected PVN or RVLM we also observed a down-regulation of AT1 
receptors and ATP2C1 when compared to the SHR SHAM group. The RVLM group has also 
 
showed down-regulation of Tpm2. Thus, it seems that there is a remodeling process in the 
hypertrophied heart of this animal model, since there is a continued improvement in gene 
expression in the heart of these animals, approaching normal levels after LVhKir2.1 treatment 
in PVN or RVLM. Moreover we show that these changes were correlated with left ventricular 
wall thickness, since the chronic treatment with LV-hKir2.1 in SHR induced regression of this 
tissue. 
 
In the common carotid artery there was an up-regulation of endothelin-2 (ET-2), endothelin 
receptor type A (Ednra) and type B (Ednrb) in LVhKir2.1 injected PVN and RVLM SHR in 
comparison to WKY rats. When compared to the sham group, the LVhKir2.1 injected PVN and 
RVLM SHR showed an up-regulation of ET-2. Interestingly, not all hypertensive conditions have 
elevated endothelin levels. It is well established that endothelin-1 (ET-1) gene expression in 
blood vessels, such aorta and mesenteric arteries of adult SHR are normal or reduced compared 
to normotensive WKY rats (Schiffrin EL, 1995; Larivière R, 1995). This is in agreement with our 
results, since ET-1 gene expression in the common carotid artery in all SHR was similar to WKY 
rats. 
 
Although ET-2 is pharmacologically indistinguishable from ET-1, we found an increase in ET-2 
gene expression in LVhKir2.1 injected SHR and ET-2 expression did not differ significantly 
between WKY and sham SHR. In a transgenic rat overexpressing ET-2 there is evidence that ET-
2 had no effect on the hypertensive condition (Paul M, 1994; Hocher B, 1996). Therefore, given 
the lack of knowledge about the biological function of endogenous ET-2, particularly in SHR 
model, it is difficult to speculate on the functional consequences of the increased ET-2 
expression levels found in common carotid artery of the SHR. 
 
The biological effects of endothelins are mediated by two receptors named Ednra and Ednrb 
receptors. In the vasculature, Ednra receptor mediates vasoconstriction (Haynes & Webb, 1993; 
Janakidevi et al., 1992) while the Ednrb receptors mediate vasodilatation through the release of 
nitric oxide and/or prostacyclin (Hirata et al., 1993; Filep et al., 1991; Schneider et al., 2007). 
Therefore, in our study, the increased expression of Ednrb receptors may improve blood flow 
through their known vasodilator function. 
 
b) Kidney 
 
In the kidneys of PVN and RVLM LVhKir2.1 injected SHR 2 of 8 genes studied were up-regulated 
(ET-1 and AT2) when compared to WKY rats. ET-1 is a potent vasoconstrictor but the role of ET-
1 in SHR remains unclear. Hughes et al found that SHR and aged-matched WKY rats had no 
difference in renal ET-1 levels until arterial hypertension (AHT) appeared. After the 
 
development of AHT the SHR had a significantly reduced ET-1 in the urine and in the outer and 
inner medulla of the kidney (Hughes et al., 1992; Largo et al., 1997). Hence, the up-regulation 
of ET-1 found in the kidneys of LVhKir2.1 injected SHR relative to normotensive rats (WKY) and 
to Sham SHR may not necessarily participate in the progression of AHT in this animal model. 
 
Wu and colleagues observed in kidneys of SHR an up-regulation in Ang II receptor AT-1 in 
comparison to WKY rats. Our data show that the LV-treatment in SHR can reverses the mRNA 
levels of AT-1 in the kidneys, since these are similar to the mRNA AT-1 levels found in WKY rats. 
This would be predicted to limit the vasoconstrictive effect of Ang II. Our results also showed an 
up-regulation in AT-2 receptor in the LVhKir2.1 injected SHR, thus contradicting the biological 
effects of AT1 receptor activation, promoting vasodilation (Oparil et al., 2003). Cosentino et al. 
showed that long-term treatment with the AT1R antagonist, losartan, in SHR promotes an 
increase in AT2R mRNA in thoracic aortas, supporting our finding about the beneficial up-
regulation of AT2R mRNA in the kidney of LVhKir2.1 injected SHR (Cosentino et al., 2005). 
 
According to several studies, there is an increase in renin mRNA expression in the kidneys of SHR 
(Antonaccio et al., 1984; Samani et al., 1989; Nakamura & Johns, 1995). Since renin release is 
regulated by the renal sympathetic nerves in the kidney we suggest that the decrease in 
sympathetic activity promoted by the LV-treatment is responsible, at least in part, for the 
decrease in renin expression found in the kidneys of LVhKir2.1 injected SHR (Skøtt & Jensen, 
1993). 
 
There is a positive correlation between the angiotensinogen levels and the blood pressure found 
in rats and in humans (Dzau VJ, 1989, El-Dahr SS, 1991, Page WV, 1992, Nakamura A, 1994; Bruna 
RD, 1993). The angiotensinogen-deficient mice do not produce angiotensinogen and are 
hypotensive reflecting the importance of angiotensinogen in the maintenance of BP and in the 
development of AHT (Pratt et al., 1989; Tanimoto et al., 1994). 
 
However, the kidneys of SHR contain lower levels of angiotensinogen mRNA compared with the 
WKY rats (Pratt et al., 1989). There is also evidence that low levels of renal sympathetic activity 
may increase angiotensinogen gene expression (Nakamura & Johns, 1994). In our study, the LV-
treatment increased the angiotensinogen mRNA in the kidneys of LVhKir2.1 injected PVN and 
RVLM SHR compared to sham SHR and to similar levels found in WKY rats an effect that may be 
related to the decreased sympathetic activity. 
 
We propose that a decrease of both blood pressure and sympathetic output contribute to the 
process of end-organ remodeling in the hypertensive state. The beneficial effect of 
 
sympathetic downregulation and/or blood pressure decrease on cardiac structure and renal 
function is well established (Amann K, 2011; Weinberg E, 1997; Bautista R, 2001; Li Y, 2010). 
However, studies using a peripheral vasodilator that only lowers blood pressure are needed to 
understand if our hypothesis is correct. 
 
In conclusion, central manipulation of sympathoexcitatory regions in the brain that promote a 
decrease in the blood pressure and sympathetic activity can affected mRNA expression in 
catdiovascular target organs, mainly through the up-regulation of angiotensinogen and AT-2 
genes in the kidney and down-regulation of AT-1 in the heart. Our data reveal the organs and 
genes that could be specifically targeted to offset the pathological consequences of 
hypertension. 
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